Replies to post #558721 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

But yet, this post is plain nonsense, exhibiting a total lack of understanding of disclaimers, and is just a tall tale with not a single iota of truth in it.

[SkyLimit2022]

The conference was about the P3, but Dr. Toms briefly mentions the combo trial at UCLA too to highlight the interim survival data.



https://clinicaltrials.gov/ct2/show/NCT04201873

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

[SkyLimit2022]

Thank you for reposting to highlight this topic again. I believe that it is important to consider that SEC filings are often used to manufacture disinformation. Without its full context, any isolated SEC disclosure is a gross distortion of reality and is misleading. SEC filings are reliable, but they are SEC filings.

Research what these documents are and what their purpose is. Compare the SEC filings for other pre-commercial biotech companies and for well-established commercial companies. By comparison, in context, and with an informed perspective, you can understand their content and their actual significance.

Who on Earth has any guarantees of future events or full control over the choices and decisions of others? Is there any valuable company with zero risk? Apple? Tesla? Amazon? Pfizer? Even the best and the biggest have risks to report. NWBO is not yet commercial, yet some seem to expect it to have fewer risks than a commercial giant?

SEC filings are solid sources. To ensure a proper and accurate understanding of their meaning, they must be read in full and in context. Furthermore, the publication date must be considered for perspective in light of subsequent developments and relevant new circumstances.

Compare any company’s filing to NVCR’s filing which lists pages and pages of risks to investors that perhaps, in an expert’s opinion, might appear much more severe than anything in the NWBO filing as a pre-commercial company. Why not consult an actual expert and compare the business outlook of both companies side-by-side? Just look at all the possible risks to their future business and investors that Novocure has included in their filing:

https://d18rn0p25nwr6d.cloudfront.net/CIK-0001645113/c5eca622-306f-417f-931b-c2ab018fa6b6.pdf#page25

sec.gov/edgar/browse/?CIK=0001072379" rel="nofollow noopener noreferrer ugc" target="_blank">https://www.sec.gov/edgar/browse/?CIK=0001072379

sec-filings/" rel="nofollow noopener noreferrer ugc" target="_blank">https://www.merck.com/investor-relations/financial-information/sec-filings/






https://www.kcl.ac.uk/people/keyoumars-%3Cspan%20style=

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847